Real-world study finds patients switching from obesity shots to Novo’s daily Wegovy pill lose 4.1% in three months
AI مارکیٹ کا خلاصہ
Real-world data presented at EASD suggests patients switching from injectable obesity therapies to Novo's oral semaglutide (Wegovy pill) achieved meaningful short-term weight loss and improved obesity classification, supporting adherence and efficacy concerns around pills. With oral therapies rising to roughly a third of U.S. obesity prescriptions and Novo capturing most new oral starts, the findings strengthen Novo's positioning versus Lilly in the fast-growing GLP-1 market.
اثر کی سطح
● درمیانہ
متاثرہ اثاثے
NCSKNVO2USD/USDT-0.96%
AI تجزیاتی سمجھ · NCSKNVO2USD/USDTAI تجزیاتی سمجھ
▲ Bullish
ابھی ٹریڈ کریں
⚠️ AI سے تیار کردہ تجزیاتی سمجھ خبروں کے مواد پر مبنی ہے اور صرف معلوماتی مقاصد کے لیے فراہم کی گئی ہے۔ یہ سرمایہ کاری کا مشورہ نہیں ہے اور نہ ہی BingX کے خیالات کی نمائندگی کرتی ہے۔ سرمایہ کاری میں رسک شامل ہے۔ براہ کرم ذمہ داری سے ٹریڈ کریں۔
A real-world study found patients who moved from injectable obesity treatments to a daily oral semaglutide pill lost an average of 4.1% of body weight over three months, or 4.0 kg, from a 221.6-pound baseline. The share classified as clinically obese fell to 65.5% from 87.1% over the same period. Nearly 41% of participants lost at least 5% of their body weight. The findings were presented at a medical conference as Novo Nordisk pushes an oral obesity option amid competition from Eli Lilly.
